Aminolevulinic acid is a chemical compound. It's part of the process your body uses to make heme, which is a key part of red blood cells. Sometimes, doctors use a special form of this acid, called Levulan, to treat certain skin growths like actinic keratosis. It works by damaging the abnormal skin cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Aminolevulinic Acid for Actinic Keratosis?
Aminolevulinic acid (ALA) is a light-activated medicine used mainly in dermatology. It is applied to the skin and then switched on with a specific lamp, a treatment called photodynamic therapy (PDT), to destroy abnormal skin cells in the treated area. Its main use is actinic keratoses: rough, scaly patches that develop on skin after years of sun exposure and that can sometimes progress to skin cancer. Two brands are used in the US. Levulan Kerastick, a 20% solution activated with blue light, is approved for actinic keratoses of the face, scalp, arms and hands. Ameluz, a 10% gel activated with red light, is approved in adults for actinic keratoses of the face and scalp, treated spot by spot or across a whole sun-damaged area. Ameluz is also approved for superficial basal cell carcinoma, a form of skin cancer that is confined to the top layers of the skin. Dermatologists also treat actinic keratoses by freezing them (cryosurgery) or with prescription creams such as fluorouracil or imiquimod. Freezing is quick and suits a few separate spots. Creams are spread over a whole sun-damaged area at home, usually for weeks, and the redness and irritation they cause is the main reason people stop them. Photodynamic therapy also treats a whole area, but in one or two clinic visits, at the cost of a painful light session and about two days out of bright light. The American Academy of Dermatology's 2021 guideline lists photodynamic therapy as a reasonable way to treat a whole area, but recommends it less firmly than the creams or freezing. Planning for up to two sessions is well supported, while the evidence that a single session clears the spots is weaker. A third product, Gleolan, contains the same ingredient but has a different job. People with a suspected high-grade glioma, a fast-growing brain tumor, drink it a few hours before surgery so that tumor tissue glows under a special microscope light, helping the surgeon see what to remove. It is an imaging aid, not a treatment: tissue that does not glow can still contain tumor, so the surgeon uses it alongside other information. The rest of this page is mainly about the skin products.
ALA itself does not react to light. After it is applied, skin cells convert it into protoporphyrin IX, a compound that is strongly light-sensitive, and it builds up in the treated skin over the following hours. That waiting period is why the light is given hours after the medicine goes on, not straight away. The clinic then shines a lamp of a matching color on the area: blue light for Levulan, red light for Ameluz. The light energizes the protoporphyrin, which reacts with oxygen to form highly reactive molecules that damage and kill the cells holding it. The treated skin then crusts, peels and heals over the following days. The same chemistry explains the main safety rule. Until the compound clears, ordinary sunlight or bright indoor light can set off the reaction too, causing an unplanned burn.
ALA skin treatment is done in a clinic by a health professional; it is not a cream to use at home. The clinician first cleans the skin, and with Ameluz also gently scrapes away scale and crust so the gel can soak in. The waiting time between application and light, called incubation, differs by product. With Levulan, the solution is painted onto each actinic keratosis. On the label schedule, face and scalp spots are lit 14 to 18 hours later, so people usually go home and return the next day, while spots on the arms are covered with a dressing and lit after 3 hours. With Ameluz, a thin layer of gel covers the spots plus a margin of normal skin, a light-blocking dressing stays on for 3 hours, and the area is lit right after the dressing comes off. Patients and staff wear protective eyewear during the light session, and the medicine should be kept away from the eyes, nose and mouth. If you cannot make it back for the light session, call the clinic and keep the area shaded anyway. One treatment is often not the end. Levulan can be repeated for spots still present after 8 weeks, and Ameluz for actinic keratoses still present after about 3 months; in Ameluz's trials, 42% of people needed a second session. Superficial basal cell carcinoma is treated with Ameluz in two sessions 1 to 2 weeks apart, with a second pair about 3 months later if the lesion has not fully cleared.
Nearly everyone has a skin reaction, because the treatment works by injuring the targeted cells. Burning or stinging during the light session is the part people notice most, and it is often intense: in Levulan's face and scalp trials at least half of participants rated it severe at one or more spots, and up to 30% did with Ameluz. It tends to peak within minutes and usually fades within a day of the light being turned off. Cooling with a fan or water mist can help, and fewer than 3% of people in Levulan's face and scalp trials stopped a session because of it. Afterwards, redness, swelling, crusting, peeling and itching at the treated sites are expected, sometimes with small blisters or oozing. These usually settle within 1 to 4 days but can last 1 to 2 weeks or longer. The treated skin can turn lighter or darker for a time, and treating the face can cause swelling around the eyes. Temporary memory loss after treatment has been reported with both products. It is rare, but if you or someone with you notices it, contact the treating clinic right away.
For about two days after application, the treated skin is highly sensitive to light. The Levulan label calls for avoiding sunlight and bright indoor light for 40 hours, and Ameluz for about 48 hours, whether or not the area was lit. Sunscreen does not protect, because visible light, not just ultraviolet light, triggers the reaction. Physical cover does: a wide-brimmed hat, long sleeves or gloves. Tanning beds, examination lamps and bright lights held close to the skin count too. If the area starts to sting or burn, get out of the light. After a Gleolan dose before brain surgery, the whole body is light-sensitive, so sunlight and bright room light are avoided for 48 hours. ALA is not used in people with porphyria, a group of rare genetic disorders in how the body makes heme (part of the oxygen-carrying machinery in blood), in people allergic to porphyrins, or in people with light-triggered skin disorders. Ameluz is also not used in people allergic to its ingredients, which include soybean phosphatidylcholine, a soy-derived substance. Allergic reactions to Ameluz have been reported and can rarely be severe. Trouble breathing, or swelling of the lips, face or throat after the gel is applied, needs emergency help immediately; call 911 if you have already left the clinic. Medicines that make skin more sensitive to light can intensify the reaction. These include tetracycline and quinolone antibiotics, sulfa drugs, thiazide diuretics (water pills for blood pressure), sulfonylurea diabetes pills, phenothiazines (a group of antipsychotic and anti-nausea medicines), the antifungal griseofulvin and the herbal supplement St. John's wort. Bring a full list of medicines and supplements to the appointment. Mention any bleeding disorder, since preparing the skin can cause bleeding and the products were not tested in people with clotting problems. Little of the topical medicine reaches the bloodstream, and the limited data have not shown a clear risk, but use in pregnancy and breastfeeding has not been formally studied. If you are pregnant or breastfeeding, discuss it with the dermatologist before treatment.
Plan the visit around the light rules. Levulan treatment of the face or scalp on the label schedule spans two days, and both products require keeping the treated area shaded for about two days afterwards, so many people schedule treatment for a time they can stay indoors. The treated area usually looks red and crusted for several days before it heals. Results are checked at a follow-up visit, about 8 weeks after Levulan and about 12 weeks after Ameluz. In the main trials, roughly two thirds of people treated with Levulan had every treated face or scalp spot clear at 8 weeks, and 84% to 91% of people treated with Ameluz had complete clearance 12 weeks after their last session, many after two sessions. These figures come from separate trials with different designs and timepoints, so they do not show that one product works better than the other. Sun-damaged skin keeps producing new spots, though. Within a year, 22% to 40% of people whose spots had cleared with Ameluz had at least one come back, so sun protection and regular skin checks stay part of care. For superficial basal cell carcinoma, Ameluz cleared the main lesion, confirmed by biopsy, in 66% of people in its main trial. Some lesions that looked clear still contained cancer under the microscope, which is why the label calls for a follow-up exam 4 to 6 weeks after each treatment cycle and skin exams every 6 to 12 months. The trials enrolled almost entirely white participants with lighter skin, so less is known about results and pigment changes in darker skin.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Aminolevulinic Acid, what you've noticed, or ask the community a question.